CA1082593A - Low temperature vapor phase sterilization and storage of biologically active injectable materials - Google Patents
Low temperature vapor phase sterilization and storage of biologically active injectable materialsInfo
- Publication number
- CA1082593A CA1082593A CA290,595A CA290595A CA1082593A CA 1082593 A CA1082593 A CA 1082593A CA 290595 A CA290595 A CA 290595A CA 1082593 A CA1082593 A CA 1082593A
- Authority
- CA
- Canada
- Prior art keywords
- container
- ethyl alcohol
- biologically active
- sodium ascorbate
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Landscapes
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Medicinal Preparation (AREA)
Abstract
ABSTRACT OF THE DISCLOSURE
A method for sterilizing solid particulate materials intended to be mixed with a liquid carrier prior to the paren-teral or hypodermic introduction into the body of humans and an-imals. The predetermined amount of particulate material is placed in a sealable container. an amount of ethyl alcohol sufficient to produce a vapor concentration in said con-tainer which is toxic to any microorganisms in the particulate material, is added to the container and the container is sealed.
When ready for use. the contents of the container may be mixed with sterile water for introduction into the body of humans and animals. This method is particularly useful with materials which tend to decompose when stored as a solution or when exposed to the conditions of normal sterilization procedures and a preferred embodiment involves the sterilization of fine crystalline sodium ascorbate.
A method for sterilizing solid particulate materials intended to be mixed with a liquid carrier prior to the paren-teral or hypodermic introduction into the body of humans and an-imals. The predetermined amount of particulate material is placed in a sealable container. an amount of ethyl alcohol sufficient to produce a vapor concentration in said con-tainer which is toxic to any microorganisms in the particulate material, is added to the container and the container is sealed.
When ready for use. the contents of the container may be mixed with sterile water for introduction into the body of humans and animals. This method is particularly useful with materials which tend to decompose when stored as a solution or when exposed to the conditions of normal sterilization procedures and a preferred embodiment involves the sterilization of fine crystalline sodium ascorbate.
Description
Conventional sterilization methods for injectable solu-tions or suspensions generally comprise the exposure of the per-formed mixture to high temperatures or ionizing radiation suffi-cient to kill any microorganisms present. This approach cannot be used with materials that will be adversely affected by the sterilizing conditions. Another approach is the sterile membrane filtration system in which the solution is passed through a ster-ile Millipore filter system. This technique can be cumbersome, involved and expensive. soth approaches, however, fail to come to grips with the problem associated with solutions which tend -to decompose relatively rapidly thereby having an intolerably low shelf life. Such materials as sodium ascorbate, for example, are available in 50 ml vials containing 25% sodium ascorbate so-lution (12.5 grams sodium ascorbate) preserved with sodium sulfite and benzyl alcohol. When such materials are used, for example, in the treatment of humans and animals in the manner described by F. R. Klenner (J. International Acad. Prev. Med., vol. 1, No.
1, pages 49-65 (1974) and W. 0. Belfield et al (J. International Acad. Prev. Med., vol. 2, No. 3, pages 10-26 (1975), and E.
Cameron et al, J. Internat. Res. Commun., vol. 1, No. 6, page 38 (1973), the sulfite produced adverse side effects resembling those of beri-beri as a result of the reaction of the sulfite with the patient's vitamin Bl. The manufacturer, upon request, has produced vials without the sulfite but the manufacturer be-lieves the shelf life is so short that they do not distribute the product through normal channels. What is needed is an inex-pensive means for sterilizing sensitive materials in the solid state so that they can be stored for long periods and mixed with sterile water immediately prior to use. This invention describes such an approach.
It is accordingly an object of this invention to pro-vide a simple economical method for sterilizing sensitive solid ,: , -- ~08ZS93 materials.
It is another object of this invention to provide a sterile container of a sensitive solid material.
A further object of this invention is to provide steri-lization with a non-toxic, volatile sterilizing agent that does not have to be removed from the mixture before use, and in the quantities employed for sterilization it would be normally meta-bolized by the body without any unfavorable side effects on in-jection.
These and other objects of this invention will be readi-ly apparent from the following description. ~ -According to this invention a stable sterile particulate solid material is prepared by a simple, non-toxic, inexpensive means in a convenient cheap disposable container. The container and contents has a long shelf life and is capable of being simply and rapidly used by the physician or nurse in the preparation of fresh injectable solutions immediately before injection into the patient.
The following description will be directed to the pre-ferred embodiment of sodium ascorbate, but it should be recognizedthat the invention can be used with combinations of sodium ascor-bate with other materials or with any other pharmaceutical mate-rial (without the presence of sodium ascorbate), that is non-reactive with ethyl alcohol.
Sodium ascorbate, for example, is rather unstable to heat both in the dry state and in solution, so that the temper-atures required for heat sterilization causes destruction and loss of activity of the ascorbate. Sterilization by sterile mem-brane filtration through a completely sterile system such as that manufactured by the Millipore Corporation can be done, but is limited to solutions. This is an expensive and time consuming operation, especially if it is necessary to first get the sodium - ~082S93 ascorbate into solution, membrane filter this solution and then freeæe-dry the sterile solution under sterile conditions to ob-tain a sterile dry powder for permanent shelf life stability in the dry state in the sterile packaged product.
Another method of sterilization, by high energy radia-tion, requires a tremendous investment in special equipment and there is no data available on the effect of such high energy ra-diation on an unstable material like sodium ascorbate as to loss in activity and the shelf life stability of radiated ascorbate.
I have overcome all these objections to present custom-ary sterilization procedures by the provision of a very simple, elegant and inexpensive, non-toxic procedure for the low-tempera-ture, vapor phase sterilization, which produces a stable parti-culate material suitable for injection purposes, with no loss of activity.
The principle of the method is to place a weighed charge of, for example, sodium ascorbate (fine crystals preferred) into a suitable sealable container (glass, plastic or other) and add a quantity of ethyl alcohol sufficient to produce a high enough concentration of alcoholic vapor to effectively kill and inactiv-ate any viable microorganisms adhering to the sodium ascorbate during the shelf-life storage time of the package containing it.
At the time the physician or nurse wants to prepare the solution for injection, they either remove or penetrate the seal with a sterile hypodermic syringe and add the required amount of sterile water for injection needed for the preparation of the solution.
The sodium ascorbate quickly dissolves and the solution is ready for injection into the patient or for further dilution for paren-teral drip therapy. No attempt is made to remove the ethyl alco-hol as the amount originally added is so small and harmless andwill be normally metabolized after injection into the patient, with no deleterious side effects or toxicity. The patient is .
:
thus assured a perfectly fresh solution of the proper ascorbate strength as the time between preparation and administration is so short that no loss of ascorbate activity can take place.
The amount of ethyl alcohol required in this treatment is very small and is easily calculated from the volume of the con-tainer and the fact that 100 milligrams of ethyl alcohol (100%) will produce approximately 50 milliliters of saturated vapor at room temperature. If a 6 ounce (170 ml) container is used, then about 360 milligrams of ethyl will be required to fill the con-tainer with ethyl alcohol vapor. Less quantities than thatgiving 100% saturation, like 50% saturation, will also be effec-tive, but I prefer to use an amount giving about 150% saturation.
Substantially larger amounts of ethyl alcohol beyond about 150%
are unnecessary and only add to the costs. The amounts of ethyl alcohol needed are so small that they do not "wet" the powder, with visible liquid in the interstices of the particulate mate-rials. Besides, keeping the ethyl alcohol levels minimal is desirable, to avoid unnecessary increases in the alcohol blood levels of the patients. The adult blood volume is about 4 liters so the ethyl alcohol added in the above example would produce an insignificant rise of about 0.01% in the alcohol blood level.
The ethyl alcohol concentration in the alcoholic liquid added to the dry particulate material is not critical, but should be preferably high to avoid adding excessive water to the mixture along with the alcohol. 100% or absolute alcohol may be employed, but the less expensive azeotropic concentration of about 95%
ethyl alcohol is preferred. Lesser concentrations can be used but require more liquid to generate the required vapor volumes.
The costs of the finished sterile product of this in-vention will be low, being not much more than the costs of theraw materials and package, as there are no involved expensive processing operations to produce sterility. This results in substantial savings to the patient in the cost of medical care.
Other materials like soluble vitamins, minerals or other drugs that are required to be injected along with the ascor-bate may be added to the sodium ascorbate in the package and the ethyl alcohol added to the mixture before the package is sealed.
In this way the other additives for injection are sterilized at the same time as the sodium ascorbate.
Sterile water "For Injection" is the preferred liquid for dissolving the treated sodium ascorbate of this invention.
I have found that if this injectable grade of water is not avail-able, particularly in veterinary medicine, boiled and cooled distilled water or even plain tap water may be used for dilution, without harmful effect on the patient.
The following are typical examples of the procedure of this patent:
Example 1. Into a clean 6 ounce screw capped bottle weigh 15 grams of sodium ascorbate fine crystals. Add 360 milligrams of ethyl alcohol (0.46 ml 95% ethyl alcohol), seal tightly and shake vigorously to distribute the alcohol and permit rapid vaporiza-tion throughout the sealed bottle. Allow to stand.Example 2. Weigh 30 grams of sodium ascorbate into a dry 1 liter plastic parenteral bag. Add 600 milligrams of ethyl alcohol (0.8 ml of 90% ethyl alcohol) and mix thoroughly with the contained powder. Fold the bag and store flat (to limit the internal vol-ume) until ready to use. Dilute with 1 liter of sterile water "For Injection", immediately before connecting to the patient.
This will produce a fresh sterile isotonic parenteral solution of sodium ascorbate suitable for continuous intravenous drip ther-apy.
Example 3. Weigh 20 grams of sodium ascorbate (fine crystals) into a 100 ml sealable vial and add 300 milligrams of ethyl alco-hol (0.48 ml 70% ethyl alcohol). Shake thoroughly and seal with -- ~08ZS93 a closure that can be sterily penetrated by a hypodermic needle.
Allow to stand. When ready for use, draw 100 ml of sterile water for injection into a sterile hypodermic syringe. Penetrate the cap with the hypodermic needle and add sufficient water to dis-solve the sodium ascorbate by swirling, without removing the hypodermic from the vial. When dissolved the solution is sucked back into the hypodermic syringe, mixed and is ready for injec-tion.
Example 4. 10 grams of sodium ascorbate (fine crystals) are weighed into a 100 ml sealable vial and 300 milligrams of ethyl alcohol is added (0.38 ml absolute alcohol) and the vial is sealed and shaken as in Example 3 and is handled similarly.
' .`
'`: ` '
1, pages 49-65 (1974) and W. 0. Belfield et al (J. International Acad. Prev. Med., vol. 2, No. 3, pages 10-26 (1975), and E.
Cameron et al, J. Internat. Res. Commun., vol. 1, No. 6, page 38 (1973), the sulfite produced adverse side effects resembling those of beri-beri as a result of the reaction of the sulfite with the patient's vitamin Bl. The manufacturer, upon request, has produced vials without the sulfite but the manufacturer be-lieves the shelf life is so short that they do not distribute the product through normal channels. What is needed is an inex-pensive means for sterilizing sensitive materials in the solid state so that they can be stored for long periods and mixed with sterile water immediately prior to use. This invention describes such an approach.
It is accordingly an object of this invention to pro-vide a simple economical method for sterilizing sensitive solid ,: , -- ~08ZS93 materials.
It is another object of this invention to provide a sterile container of a sensitive solid material.
A further object of this invention is to provide steri-lization with a non-toxic, volatile sterilizing agent that does not have to be removed from the mixture before use, and in the quantities employed for sterilization it would be normally meta-bolized by the body without any unfavorable side effects on in-jection.
These and other objects of this invention will be readi-ly apparent from the following description. ~ -According to this invention a stable sterile particulate solid material is prepared by a simple, non-toxic, inexpensive means in a convenient cheap disposable container. The container and contents has a long shelf life and is capable of being simply and rapidly used by the physician or nurse in the preparation of fresh injectable solutions immediately before injection into the patient.
The following description will be directed to the pre-ferred embodiment of sodium ascorbate, but it should be recognizedthat the invention can be used with combinations of sodium ascor-bate with other materials or with any other pharmaceutical mate-rial (without the presence of sodium ascorbate), that is non-reactive with ethyl alcohol.
Sodium ascorbate, for example, is rather unstable to heat both in the dry state and in solution, so that the temper-atures required for heat sterilization causes destruction and loss of activity of the ascorbate. Sterilization by sterile mem-brane filtration through a completely sterile system such as that manufactured by the Millipore Corporation can be done, but is limited to solutions. This is an expensive and time consuming operation, especially if it is necessary to first get the sodium - ~082S93 ascorbate into solution, membrane filter this solution and then freeæe-dry the sterile solution under sterile conditions to ob-tain a sterile dry powder for permanent shelf life stability in the dry state in the sterile packaged product.
Another method of sterilization, by high energy radia-tion, requires a tremendous investment in special equipment and there is no data available on the effect of such high energy ra-diation on an unstable material like sodium ascorbate as to loss in activity and the shelf life stability of radiated ascorbate.
I have overcome all these objections to present custom-ary sterilization procedures by the provision of a very simple, elegant and inexpensive, non-toxic procedure for the low-tempera-ture, vapor phase sterilization, which produces a stable parti-culate material suitable for injection purposes, with no loss of activity.
The principle of the method is to place a weighed charge of, for example, sodium ascorbate (fine crystals preferred) into a suitable sealable container (glass, plastic or other) and add a quantity of ethyl alcohol sufficient to produce a high enough concentration of alcoholic vapor to effectively kill and inactiv-ate any viable microorganisms adhering to the sodium ascorbate during the shelf-life storage time of the package containing it.
At the time the physician or nurse wants to prepare the solution for injection, they either remove or penetrate the seal with a sterile hypodermic syringe and add the required amount of sterile water for injection needed for the preparation of the solution.
The sodium ascorbate quickly dissolves and the solution is ready for injection into the patient or for further dilution for paren-teral drip therapy. No attempt is made to remove the ethyl alco-hol as the amount originally added is so small and harmless andwill be normally metabolized after injection into the patient, with no deleterious side effects or toxicity. The patient is .
:
thus assured a perfectly fresh solution of the proper ascorbate strength as the time between preparation and administration is so short that no loss of ascorbate activity can take place.
The amount of ethyl alcohol required in this treatment is very small and is easily calculated from the volume of the con-tainer and the fact that 100 milligrams of ethyl alcohol (100%) will produce approximately 50 milliliters of saturated vapor at room temperature. If a 6 ounce (170 ml) container is used, then about 360 milligrams of ethyl will be required to fill the con-tainer with ethyl alcohol vapor. Less quantities than thatgiving 100% saturation, like 50% saturation, will also be effec-tive, but I prefer to use an amount giving about 150% saturation.
Substantially larger amounts of ethyl alcohol beyond about 150%
are unnecessary and only add to the costs. The amounts of ethyl alcohol needed are so small that they do not "wet" the powder, with visible liquid in the interstices of the particulate mate-rials. Besides, keeping the ethyl alcohol levels minimal is desirable, to avoid unnecessary increases in the alcohol blood levels of the patients. The adult blood volume is about 4 liters so the ethyl alcohol added in the above example would produce an insignificant rise of about 0.01% in the alcohol blood level.
The ethyl alcohol concentration in the alcoholic liquid added to the dry particulate material is not critical, but should be preferably high to avoid adding excessive water to the mixture along with the alcohol. 100% or absolute alcohol may be employed, but the less expensive azeotropic concentration of about 95%
ethyl alcohol is preferred. Lesser concentrations can be used but require more liquid to generate the required vapor volumes.
The costs of the finished sterile product of this in-vention will be low, being not much more than the costs of theraw materials and package, as there are no involved expensive processing operations to produce sterility. This results in substantial savings to the patient in the cost of medical care.
Other materials like soluble vitamins, minerals or other drugs that are required to be injected along with the ascor-bate may be added to the sodium ascorbate in the package and the ethyl alcohol added to the mixture before the package is sealed.
In this way the other additives for injection are sterilized at the same time as the sodium ascorbate.
Sterile water "For Injection" is the preferred liquid for dissolving the treated sodium ascorbate of this invention.
I have found that if this injectable grade of water is not avail-able, particularly in veterinary medicine, boiled and cooled distilled water or even plain tap water may be used for dilution, without harmful effect on the patient.
The following are typical examples of the procedure of this patent:
Example 1. Into a clean 6 ounce screw capped bottle weigh 15 grams of sodium ascorbate fine crystals. Add 360 milligrams of ethyl alcohol (0.46 ml 95% ethyl alcohol), seal tightly and shake vigorously to distribute the alcohol and permit rapid vaporiza-tion throughout the sealed bottle. Allow to stand.Example 2. Weigh 30 grams of sodium ascorbate into a dry 1 liter plastic parenteral bag. Add 600 milligrams of ethyl alcohol (0.8 ml of 90% ethyl alcohol) and mix thoroughly with the contained powder. Fold the bag and store flat (to limit the internal vol-ume) until ready to use. Dilute with 1 liter of sterile water "For Injection", immediately before connecting to the patient.
This will produce a fresh sterile isotonic parenteral solution of sodium ascorbate suitable for continuous intravenous drip ther-apy.
Example 3. Weigh 20 grams of sodium ascorbate (fine crystals) into a 100 ml sealable vial and add 300 milligrams of ethyl alco-hol (0.48 ml 70% ethyl alcohol). Shake thoroughly and seal with -- ~08ZS93 a closure that can be sterily penetrated by a hypodermic needle.
Allow to stand. When ready for use, draw 100 ml of sterile water for injection into a sterile hypodermic syringe. Penetrate the cap with the hypodermic needle and add sufficient water to dis-solve the sodium ascorbate by swirling, without removing the hypodermic from the vial. When dissolved the solution is sucked back into the hypodermic syringe, mixed and is ready for injec-tion.
Example 4. 10 grams of sodium ascorbate (fine crystals) are weighed into a 100 ml sealable vial and 300 milligrams of ethyl alcohol is added (0.38 ml absolute alcohol) and the vial is sealed and shaken as in Example 3 and is handled similarly.
' .`
'`: ` '
Claims (4)
1. A method for sterilizing and storing a biologically active particulate solid material adapted for injection into a patient which comprises:
a) placing a charge of the material in a sealable con-tainer b) adding to said container an amount of ethyl alcohol sufficient to produce a sterilizing ethyl alcohol vapor in said container c) sealing said container, and d) storing said sealed container for a period of time at least sufficient to sterilize said material.
a) placing a charge of the material in a sealable con-tainer b) adding to said container an amount of ethyl alcohol sufficient to produce a sterilizing ethyl alcohol vapor in said container c) sealing said container, and d) storing said sealed container for a period of time at least sufficient to sterilize said material.
2. The method of claim 1 wherein said solid material com-prises sodium ascorbate.
3. An article of manufacture comprising a sealed disposable container containing an amount of biologically active solid particulate material adapted for injection into a patient and an amount of ethyl alcohol sufficient to generate a sterilizing vapor of ethyl alcohol in said container.
4. The article of claim 3 wherein said biologically active material comprises sodium ascorbate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA290,595A CA1082593A (en) | 1977-11-10 | 1977-11-10 | Low temperature vapor phase sterilization and storage of biologically active injectable materials |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA290,595A CA1082593A (en) | 1977-11-10 | 1977-11-10 | Low temperature vapor phase sterilization and storage of biologically active injectable materials |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1082593A true CA1082593A (en) | 1980-07-29 |
Family
ID=4109995
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA290,595A Expired CA1082593A (en) | 1977-11-10 | 1977-11-10 | Low temperature vapor phase sterilization and storage of biologically active injectable materials |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA1082593A (en) |
-
1977
- 1977-11-10 CA CA290,595A patent/CA1082593A/en not_active Expired
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4282863A (en) | Methods of preparing and using intravenous nutrient compositions | |
| US4906103A (en) | Devices and methods for preparing a solution for medicinal purposes | |
| BR9300278A (en) | PLASTIC SYRINGE PREVIOUSLY FILLED TO AUTOCLAVE A STERILIZABLE MATERIAL, AND PROCESS OF TERMINATELY STERILIZING A MATERIAL IN A SYRINGE FOR CHEMICAL / PHARMACEUTICAL USE | |
| JP3158197B2 (en) | System for creating parenteral solutions at points remote from aseptic environment | |
| RU94046305A (en) | Device for controlled mixing of first component and second liquid component | |
| KR870000918A (en) | Pharmaceutical dosage unit | |
| US3914419A (en) | Two compartment one unit consecutively injectable liquid vitamin package | |
| US4058213A (en) | Low temperature vapor phase sterilization and storage of biologically active injectable materials | |
| JP2003024415A (en) | Injectable solution vessel | |
| AU763195B2 (en) | Bag for preserving and transporting sterile products in powder form and for forming solutions of said products in the bag | |
| CA1082593A (en) | Low temperature vapor phase sterilization and storage of biologically active injectable materials | |
| WO2019213268A1 (en) | Ready-to-use liquid parenteral formulations of ribavirin | |
| GB1566346A (en) | Sterilizing a particulate solid material | |
| Stiles et al. | Stability of fluorouracil administered through four portable infusion pumps | |
| Boylan et al. | Parenteral products | |
| Boylan et al. | Parenteral products | |
| Chapman | Parenteral products | |
| US4292312A (en) | Method for preparing alloxan stable aqueous solutions and solutions resulting therefrom | |
| JP4680454B2 (en) | Aseptic calcitonin preparation and method for producing the same | |
| JPH04500817A (en) | Nutritional composition and method for its preparation | |
| NL1006135C2 (en) | Apparatus and method for preparing radioactive drugs for administration. | |
| US3063904A (en) | Polymeric oxygen in blood and sera treatment and the product thereof | |
| WO1983000430A1 (en) | Methods of preparing and using intravenous nutrient compositions | |
| JP2000212099A (en) | Therapeutic agent for viral hepatitis | |
| DE2750167A1 (en) | Sterilisation of biological materials - esp. sodium ascorbate by storage in ethanol vapour in sealed container |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |